c-Fms

<p>Edicotinib (JNJ-527) is a blood-brain permeable, selective CSF-1R inhibitor, with lesser inhibitory effects on KIT and FLT3.Cost-effective and quality-assured.</p>

<p>Emactuzumab(RG 7155) is a monoclonal antibody against colony-stimulating factor-1 receptor targeting tumor-associated macrophages (TAMs) Emactuzumab has</p>

<p>Lacnotuzumab (MCS110) is a humanized monoclonal antibody targeting CSF-1, which can be used in research on retinal diseases.</p>

<p>CSF1R-IN-1 is a CSF1R inhibitor with IC50 of 0.5 nM.</p>

<p>Axatilimab (SNDX-6352) is a human IgG4 antibody that targets CSF-1R and can be used to study immune system diseases and respiratory diseases.</p>

<p>Mavrilimumab (CAM 3001), a monoclonal antibody, blocks GM-CSF signaling, potentially reducing inflammation in rheumatoid arthritis.</p>

<p>CSF1R-IN-2 is an oral-active SRC, MET and c-FMS inhibitor (IC50s: 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively).</p>

<p>PXB17 inhibits CSF1R activation (IC50= 1.7 nM) by blocking the PI3K/AKT/mTORC1 signaling pathway. It is effective orally, significantly suppresses the growth of colorectal cancer (CRC), enhances the efficacy of PD-1 monoclonal antibodies (PD-1mAb), and reduces the recurrence of CRC tumors.</p>

<p>M4205 is an inhibitor of c-Kit exhibiting high activity on c-Kit mutations in exons 11, 13, 17.</p>

<p>CSF1R-IN-17 (compound 9) is a potent, selective antagonist of CSF1R, exhibiting an inhibition concentration half-maximum (IC50) of 0.2 nM.</p>

<p>Pyrithyldione is a sedative-hypnotic agent known to potentially induce agranulocytosis.</p>

<p>AMG-820 is a human antibody targeting CSF-1R, inhibiting the binding of ligands CSF1 and IL34, and preventing subsequent ligand-induced receptor activation. For AMG-820's isotype control, refer to [Human IgG2 kappa, Isotype Control].</p>

<p>PLX647 dihydrochloride: potent FMS/KIT inhibitor (IC50: 28/16 nM), highly selective, limited FLT3/KDR activity, oral use.</p>

<p>cFMS Receptor Inhibitor IV is an inhibitor of c-Fms tyrosine kinase.</p>

<p>Otilimab, a humanized monoclonal antibody, blocks GM-CSF to reduce inflammation and may treat severe COVID-19 pneumonia.</p>

<p>Sotuletinib hydrochloride (BLZ945 HCl) is a selective, brain-penetrant CSF-1R (c-Fms) inhibitor (IC50=1 nM),for ALS and TNBC.</p>

<p>GENZ-882706(Raceme) is the racemate of GENZ-882706.</p>

<p>PD-360324 is a human monoclonal antibody (mAb) that targets CSF1/M-CSF. It can be utilized in research related to skin lupus, pulmonary sarcoidosis, and rheumatoid arthritis.</p>

<p>Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.</p>

<p>Plonmarlimab(TJ003234) is an anti-GM-CSF monoclonal antibody with potential antiviral activity for the study of immune disorders and novel coronavirus infection</p>

<p>Eflapegrastim: humanized IgG4 antibody and G-CSF that boosts neutrophils and shortens neutropenia.</p>

<p>Gimsilumab (MORAb-022) is an anti-c-Fms humanized monoclonal antibody for the study of inflammation and hypoxemia caused by COVID-19.</p>

<p>M-CSFR/CSF1R/CD115 Protein, Cynomolgus, Recombinant (His) is expressed in HEK293 mammalian cells with C-His tag.</p>

<p>Anti-CSF1R Antibody (1R707) is a Rabbit antibody targeting CSF1R. Anti-CSF1R Antibody (1R707) can be used in ELISA.</p>

<p>Anti-CSF1R Antibody (2I506) is a Mouse antibody targeting CSF1R. Anti-CSF1R Antibody (2I506) can be used in ELISA.</p>

<p>Anti-CSF1R Antibody-FITC (4Y587) is a FITC-conjugated Mouse antibody targeting CSF1R. Anti-CSF1R Antibody-FITC (4Y587) can be used in FCM.</p>

<p>Anti-CSF1R Antibody (7V18) is a Rabbit antibody targeting CSF1R. Anti-CSF1R Antibody (7V18) can be used in ELISA.</p>

<p>Anti-CSF1R Antibody (8O797) is a Mouse antibody targeting CSF1R. Anti-CSF1R Antibody (8O797) can be used in ELISA.</p>

<p>Anti-CSF1R Antibody (5B661) is a Mouse antibody targeting CSF1R. Anti-CSF1R Antibody (5B661) can be used in ELISA,ELISA(Cap).</p>

<p>Anti-CSF1R Antibody (5C535) is a Rabbit antibody targeting CSF1R. Anti-CSF1R Antibody (5C535) can be used in ELISA.</p>

<p>CSF1R Protein, Human, Recombinant (His &amp; Avi), Biotinylated is expressed in HEK293 mammalian cells with His and Avi tag.</p>

<p>CSF1R Protein (Met1-Glu512), Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag.</p>

<p>CSF1R Protein, Human, Recombinant (hFc) is expressed in HEK293 mammalian cells with hFc tag.</p>

<p>M-CSFR/CSF1R/CD115 Protein, Human, Recombinant (His &amp; Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag.</p>

<p>CSF1R Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 55.1 kDa and the accession number is P07333-1.</p>

<p>CSF1R Protein, Human, Recombinant (His &amp; GST) is expressed in Baculovirus insect cells with His and GST tag.</p>

<p>CSF1R Protein, Human, Recombinant (mFc) is expressed in HEK293 mammalian cells with mFc tag.</p>

<p>CSF1R Protein (Ala299-Glu512), Human, Recombinant (His) is expressed in HEK293 mammalian cells with His tag.</p>

<p>CSF1R Protein, Human, Recombinant (hFc &amp; Avi), Biotinylated is expressed in HEK293 mammalian cells with hFc and Avi tag.</p>

<p>CSF1R Protein, Human, Recombinant (Domain I&amp;II&amp;III, His) is expressed in HEK293 mammalian cells with His tag.</p>

<p>PLX647 is a highly selective dual FMS/KIT kinase inhibitor (IC50: 28/16 nM).</p>

<p>M-CSFR/CSF1R/CD115 Protein, Human, Recombinant (His &amp; Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag.</p>

<p>Anti-CSF1R Antibody (4Y587) is a Mouse antibody targeting CSF1R. Anti-CSF1R Antibody (4Y587) can be used in FCM.</p>

<p>Pazopanib HCl (Votrient) inhibits VEGFR1-3, PDGFR, FGFR, c-Kit, c-Fms with IC50 range 10-146 nM in cell-free assays.</p>

<p>Seralutinib (GB002) is an inhibitor of inhaled PDGFRα and PDGFRβ. It is used in the study for pulmonary arterial hypertension.</p>

<p>AZD7507 is a CSF-1R inhibitor with an IC50 of 32 nM. AZD7507 has antitumor activity.</p>

<p>PRN1371 is a specific and potent FGFR1-4 and CSF1R inhibitor (IC50s: 0.6/1.3/4.1/19.3/8.1 nM for FGFR1/2/3/4 and CSF1R).</p>

<p>Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential</p>

<p>cFMS Receptor Inhibitor II is a CSF1R kinase inhibitor</p>

<p>PF 477736 (PF-736,PF-00477736) is a specifc, effective and ATP-competitive Chk1 inhibitor (Ki: 0.49 nM ) and also inhibits FGFR3, Aurora-A, VEGFR2, Flt3, Fms (</p>

<p>Ki-20227 is a specific c-Fms tyrosine kinase(CSF1R) inhibitor (IC50: 2 nM).</p>

<p>Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor (IC50s: &lt;0.01 μM and 0.1-1 μM).</p>

<p>Sotuletinib (BLZ945) is an orally active, effective and specific CSF-1R inhibitor, &gt;1000-fold selective against its closest receptor tyrosine kinase homologs.</p>

<p>AZ304 is an ATP-competitive dual BRAF kinase inhibitor, potently inhibits BRAF (WT), BRAF (V600E), and wild type CRAF (IC50s: 79/38/68 nM).</p>

<p>GW2580 (SC-203877) is a specific, oral-bioavailable CSF-1R inhibitor for c-FMS.</p>

<p>PLX5622 is a selective, orally active and blood-brain barrier permeable CSF1R inhibitor. PLX5622 induces elimination of microglia. Cost effective and quality assured.</p>

<p>Linifanib (AL-39324) (ABT-869) is a novel, potent ATP-competitive VEGFR/PDGFR inhibitor for KDR (IC50: 4 nM), CSF-1R (IC50: 3 nM), Flt-1/3 (IC50: 3/4 nM) and</p>

<p>Nampt-IN-1 (LSN3154567) (LSN3154567) is a potent and selective NAMPT inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC50 of 3.1 nM.</p>

<p>OSI-930 is an oral c-Kit/VEGFR-2 inhibitor targeting tumor growth and angiogenesis.</p>

<p>Dovitinib is an orally active, multi-targeted tyrosine kinase (RTK) inhibitor with anti-tumor effects.Cost-effective and quality-assured.</p>

<p>Anumigilimab (CSL-324) is a fully human therapeutic anti-G-CSFR antibody with potential anti-tumor activity for the study of inflammation.</p>

<p>Lenzilumab (KB 003) is a humanized GM-CSF neutralizing antibody for the study of COVID-19.</p>

<p>Namilumab (AMG203) is a humanised IgG1 monoclonal antibody that neutralises GM-CSF. rheumatoid arthritis and active axial spondyloarthritis.</p>

<p>Trabikibart (CSL311) is a human βc-specific antibody inhibiting IL-3, GM-CSF and IL-5, regulating eosinophil survival in chronic inflammatory disease research.</p>

<p>Cabiralizumab is an anti-CSF1R monoclonal antibody that enhances T cell infiltration, inhibits osteoclasts, and is used in RA and immune-oncology research.</p>

<p>Anti-Mouse GM-CSF Antibody is a rat-derived IgG2a isotype inhibitor that targets mouse granulocyte-macrophage colony-stimulating factor (GM-CSF).</p>

<p>CSF1R-IN-19 is a robust inhibitor of CSF1R that influences the exchange of inflammatory factors between TAMs and glioma cells. It holds potential for cancer research [1].</p>

<p>Sotuletinib (BLZ945) dihydrochloride is an orally administered, blood-brain barrier-permeable inhibitor specifically targeting CSF1-R with an IC50 of 1 nM.</p>

<p>c-Fms-IN-9 inhibits c-FMS/uFMS and uKIT with IC50 &lt;0.01μM and 0.1-1μM, from patent WO2014145023A1.</p>

<p>Leustroducsin A is an inducer of colony-stimulating factors (CSFs) extracted from Streptomyces platensis SANK 60191.</p>

<p>c-Fms-IN-7 is a cFMS inhibitor (IC50: 18.5 nM).</p>

<p>c-Fms-IN-8 is a colony-stimulating factor-1 receptor (CSF-1R, c-FMS) Type II inhibitor (IC50: 9.1 nM). It is compound 4a in the reference.</p>

<p>JNJ-28312141: oral CSF1R/FLT3 inhibitor, potential for treating acute myeloid leukemia, tumors, and bone events.</p>

<p>CSF1R-IN-4, a potent CSF-1R inhibitor, may impact TAM/glioma cell communication, with cancer research potential. (WO2021197276A1, compound 104)</p>

<p>c-Fms-IN-10 is a thieno[3,2-d]pyrimidine derivative, an FMS kinase inhibitor with IC50 of 2 nM, exhibiting anti-tumor properties.</p>

<p>CSF1R-IN-13: potent cancer research CSF1R inhibitor impacting cell growth regulation.</p>

<p>CSF1R-IN-8 (Compound 22) is a CSF-1R inhibitor (IC50: 0.012 μM).</p>

<p>CSF1R-IN-10 (Compound 48) is a CSF-1R inhibitor (IC50: 0.005 μM).</p>

<p>Leustroducsin C is an inducer of colony-stimulating factors CSF extracted from Streptomyces platensis SANK 60191.</p>

<p>CSF1R-IN-14, an isoindolinone derivative, powerfully inhibits CSF1R, with potential in cancer research. See WO2019134662A1, compound 1.</p>

<p>CSF1R-IN-12 is an effective CSF1R inhibitor. CSF1R-IN-12 has research potential in cancer diseases.</p>

<p>CSF1R-IN-7 is a highly selective CSF-1R inhibitor with good brain penetration for treatment of diseases associated with microglia-mediated neuroinflammation.</p>

<p>CSF1R-IN-9 (Compound 46) is a CSF-1R inhibitor (IC50: 0.028 μM).</p>

<p>CSF1R-IN-6, a compound, effectively inhibits macrophage CSF1R essential for survival and differentiation.</p>

<p>c-Fms-IN-2 is an inhibitor of c-FMS kinase (IC50 = 24 nM).</p>

<p>ABD-295, a biphenylsulfide derivative, inhibits osteoclasts and prevents bone loss in vitro and in vivo.</p>

<p>c-Fms-IN-6 is a potent inhibitor of c-FMS (IC50 ≤10 nM for unphosphorylated c-FMS) and also weakly inhibits unphosphorylated c-KIT and PDGFR (IC50: &gt; 1 μM).</p>

<p>IACS-9439 is a potent, selective, and orally active inhibitor of CSF1R, exhibiting a K(i) of 1 nM.</p>

<p>c-Fms-IN-1 is an inhibitor of c-FMS kinase (IC50 = 0.8 nM).</p>

<p>Chiauranib, a potent anticancer agent, inhibits angiogenesis kinases (VEGFR1-3, PDGFRα, c-Kit), Aurora B, and CSF1R with IC50 values of 1-9 nM.</p>

<p>c-Fms-IN-3 is a novel inhibitor of the c-FMS and can be used in studies about antirheumatic and anti-inflammatory diseases.</p>

<p>c-Fms-IN-13 (compound 14) is a potent FMS kinase inhibitor (IC50= 17 nM). c-Fms-IN-13 is an anti-inflammatory agent.</p>

<p>Pimicotinib (ABSK021) is a potent CSF1R inhibitor with antitumor activity and can be used to study advanced solid tumors.</p>

<p>CSF1R-IN-3 is an orally effective CSF-1R inhibitor with an IC50 value of 2.1 nM.</p>

<p>c-Fms-IN-14 (Example 76) is a potent inhibitor of the c-Fms kinase with an IC50 of 4 nM, utilized in cancer and autoimmune disease research [1].</p>

<p>Axl/Mer/CSF1R-IN-2 (Comp 4) serves as an inhibitor for Axl, Mer, and CSF1R [1].</p>

<p>Axl/Mer-IN-1 is a compound that functions as an inhibitor for Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R, exhibiting dissociation constants (Kds)</p>

<p>Ataquimast is used in curing advanced receptor-positive breast cancer.</p>

<p>JTE-952: oral, selective Type II CSF-1R inhibitor, IC50 = 13 nM for CSF1R, 261 nM for TrkA, effective in mouse arthritis model.</p>

<p>CSF1R-IN-5: Potent CSF1R inhibitor, may alter TAM/glioma inflammatory exchanges, potential cancer research tool. (WO2021197276A1, Compound 11)</p>